NCT06699966View on ClinicalTrials.gov

Stony Brook Medicine Anti-Inflammatory Trial

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

June 30, 2030

Study Completion Date

January 31, 2031

Conditions
Major Depressive Disorder
Interventions
DRUG

Celecoxib

The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.

DRUG

Minocycline

Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.

All Listed Sponsors
lead

Stony Brook University

OTHER